CAMK2B

Across TCGA pan-cancer cohorts, CAMK2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAMK2B data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAMK2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CAMK2B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where CAMK2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.901	0.429	.007	12	view →
CCRCC	OS	Median	All	1.000	0.916	.026	7	view →
LSCC	DFS	Median	All	0.892	1.000	.035	5	view →
GBM	DFS	Tertile	All	0.828	0.695	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAMK2B–PDAC (DFS)

Open the PDAC breakdown →